S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
NASDAQ:GRTX

Galera Therapeutics Price Target, Predictions & Analyst Ratings

$1.28
+0.01 (+0.79%)
(As of 12/6/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.19
$1.29
50-Day Range
$1.27
$8.40
52-Week Range
$1.19
$12.99
Volume
880,323 shs
Average Volume
1.02 million shs
Market Capitalization
$33.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12

Galera Therapeutics (NASDAQ:GRTX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 5 Analyst Ratings

Analyst Price Target Consensus

$14.60
1,040.63% Upside

High PT$30.00
Average PT$14.60
Low PT$2.00
TypeCurrent
12/7/20 to 12/7/21
1 Month Ago
11/7/20 to 11/7/21
3 Months Ago
9/8/20 to 9/8/21
1 Year Ago
12/8/19 to 12/7/20
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$14.60$14.60$17.00$15.00
Price Target Upside1,040.63% Upside178.63% Upside78.23% Upside40.90% Upside
Get Galera Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Galera Therapeutics (NASDAQ:GRTX) vs. Its Competitors

TypeGalera TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.72
2.57
Consensus RatingHoldBuyBuy
Price Target Upside1,040.63% Upside1,541.39% Upside12.11% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
39
59.09%
Underperform Votes
27
40.91%
Avg. Outperform Votes
176
67.43%
Avg. Underperform Votes
85
32.57%
Avg. Outperform Votes
834
69.44%
Avg. Underperform Votes
367
30.56%

Galera Therapeutics (NASDAQ:GRTX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/21/2021Citigroup
Lower Price TargetBuy$21.00 ➝ $11.00+416.43%
10/20/2021HC Wainwright
Ram Selvaraju
DowngradeBuy ➝ Neutral
10/19/2021Bank of America
DowngradeBuy ➝ Underperform$17.00 ➝ $2.00-11.11%
10/19/2021BTIG Research
DowngradeBuy ➝ Neutral
4/26/2021Credit Suisse Group
Initiated CoverageOutperform$15.00+76.89%
10/28/2020Smith Barney Citigroup
Boost Price Target$18.00 ➝ $21.00+103.69%
(Data available from 12/7/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Galera Therapeutics (NASDAQ:GRTX) Analyst Ratings Frequently Asked Questions

What is Galera Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Galera Therapeutics stock is Hold based on the current 1 sell rating, 2 hold ratings and 2 buy ratings for GRTX. The average twelve-month price target for Galera Therapeutics is $14.60 with a high price target of $30.00 and a low price target of $2.00. Learn more on GRTX's analyst rating history

Do Wall Street analysts like Galera Therapeutics more than its competitors?

Analysts like Galera Therapeutics stock less than the stock of other Medical companies. The consensus rating for Galera Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how GRTX compares to other companies

Do MarketBeat users like Galera Therapeutics more than its competitors?

MarketBeat users like Galera Therapeutics stock less than the stock of other Medical companies. 59.09% of MarketBeat users gave Galera Therapeutics an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.

Is Galera Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Galera Therapeutics's stock had 3 downgrades by analysts.

Does Galera Therapeutics's stock price have much upside?

According to analysts, Galera Therapeutics's stock has a predicted upside of 178.63% based on their 12-month price targets.

What analysts cover Galera Therapeutics?

Galera Therapeutics has been rated by Bank of America, BTIG Research, Citigroup, and HC Wainwright in the past 90 days.

This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.